Role of osteopontin in lung cancer evolution and heterogeneity

Seminars in Cell and Developmental Biology

Volumn 64, Issue , 2017, Pages 40-47

  Shi, Lin ^a   Wang, Xiangdong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Heterogeneity; Isoform; Lung cancer; Metastasis; Osteopontin

Indexed keywords

OSTEOPONTIN; ISOPROTEIN;

GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; LUNG CANCER; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; DISEASE EXACERBATION; GENE REGULATORY NETWORK; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; GENE REGULATORY NETWORKS; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; OSTEOPONTIN; PROTEIN ISOFORMS;

EID: 84994461932     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2016.08.032     Document Type: Review

References (88)

1. Prince, C.W., Oosawa, T., Butler, W.T., Tomana, M., Bhown, A.S., Bhown, M., et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J. Biol. Chem. 262 (1987), 2900–2907.
2. Xie, X., Ma, S., Li, C., Liu, P., Wang, H., Chen, L., et al. Expression of small integrin-binding LIgand N-linked glycoproteins (SIBLINGs) in the reparative dentin of rat molars. Dent. Traumatol. 30 (2014), 285–295.
3. Ramaiah, S.K., Rittling, S., Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 103 (2008), 4–13.
4. Rangaswami, H., Bulbule, A., Kundu, G.C., Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 16 (2006), 79–87.
5. Denhardt, D.T., Guo, X., Osteopontin: a protein with diverse functions. FASEB J. 7 (1993), 1475–1482.
6. Gardner, H.A., Berse, B., Senger, D.R., Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9 (1994), 2321–2326.
7. Hu, Z., Lin, D., Yuan, J., Xiao, T., Zhang, H., Sun, W., et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin. Cancer Res. 11 (2005), 4646–4652.
8. Wang, X.M., Li, J., Yan, M.X., Liu, L., Jia, D.S., Geng, Q., et al. Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One, 8, 2013, e55714.
9. Sun, B.S., You, J., Li, Y., Zhang, Z.F., Wang, C.L., Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. Chin. Med. J. (Engl.) 126 (2013), 1683–1688.
10. Zou, X.L., Wang, C., Liu, K.E., Nie, W., Ding, Z.Y., Prognostic significance of osteopontin expression in non-small-cell lung cancer: a meta-analysis. Mol. Clin. Oncol. 3 (2015), 633–638.
11. Donati, V., Boldrini, L., Dell'Omodarme, M., Prati, M.C., Faviana, P., Camacci, T., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin. Cancer Res. 11 (2005), 6459–6465.
12. Boldrini, L., Donati, V., Dell'Omodarme, M., Prati, M.C., Faviana, P., Camacci, T., et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br. J. Cancer 93 (2005), 453–457.
13. O'Regan, A., Berman, J.S., Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81 (2000), 373–390.
14. Singh, K., DeVouge, M.W., Mukherjee, B.B., Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J. Biol. Chem. 265 (1990), 18696–18701.
15. Franzen, A., Heinegard, D., Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 232 (1985), 715–724.
16. Kurzbach, D., Platzer, G., Schwarz, T.C., Henen, M.A., Konrat, R., Hinderberger, D., Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry 52 (2013), 5167–5175.
17. Young, M.F., Kerr, J.M., Termine, J.D., Wewer, U.M., Wang, M.G., McBride, O.W., et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7 (1990), 491–502.
18. Platzer, G., Schedlbauer, A., Chemelli, A., Ozdowy, P., Coudevylle, N., Auer, R., et al. The metastasis-associated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites. Biochemistry 50 (2011), 6113–6124.
19. Yokosaki, Y., Matsuura, N., Sasaki, T., Murakami, I., Schneider, H., Higashiyama, S., et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J. Biol. Chem. 274 (1999), 36328–36334.
20. Oldberg, A., Franzen, A., Heinegard, D., Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 8819–8823.
21. Sodek, J., Ganss, B., Osteopontin, McKee M.D., Critical reviews in oral biology and medicine: an official publication of the American Association of Oral. Biologists 11 (2000), 279–303.
22. O'Regan, A.W., Chupp, G.L., Lowry, J.A., Goetschkes, M., Mulligan, N., Berman, J.S., Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J. Immunol. 162 (1999), 1024–1031.
23. Denhardt, D.T., Mistretta, D., Chambers, A.F., Krishna, S., Porter, J.F., Raghuram, S., et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 20 (2003), 77–84.
24. Chuang, C.Y., Chang, H., Lin, P., Sun, S.J., Chen, P.H., Lin, Y.Y., et al. Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 492 (2012), 262–269.
25. El-Tanani, M., Platt-Higgins, A., Rudland, P.S., Campbell, F.C., Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J. Biol. Chem. 279 (2004), 20794–20806.
26. Chagan-Yasutan, H., Tsukasaki, K., Takahashi, Y., Oguma, S., Harigae, H., Ishii, N., et al. Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia. Leuk. Res. 35 (2011), 1484–1490.
27. Boudjadi, S., Bernatchez, G., Beaulieu, J.F., Carrier, J.C., Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am. J. Pathol. 183 (2013), 266–276.
28. Mitra, A., Menezes, M.E., Pannell, L.K., Mulekar, M.S., Honkanen, R.E., Shevde, L.A., et al. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3beta to downregulate beta-catenin transcription target, osteopontin. Oncogene 31 (2012), 4472–4483.
29. Samant, R.S., Clark, D.W., Fillmore, R.A., Cicek, M., Metge, B.J., Chandramouli, K.H., et al. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol. Cancer, 6, 2007, 6.
30. Das, S., Harris, L.G., Metge, B.J., Liu, S., Riker, A.I., Samant, R.S., et al. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J. Biol. Chem. 284 (2009), 22888–22897.
31. El-Tanani, M.K., Campbell, F.C., Crowe, P., Erwin, P., Harkin, D.P., Pharoah, P., et al. BRCA1 suppresses osteopontin-mediated breast cancer. J. Biol. Chem. 281 (2006), 26587–26601.
32. Hedley, B.D., Welch, D.R., Allan, A.L., Al-Katib, W., Dales, D.W., Postenka, C.O., et al. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int. J. Cancer 123 (2008), 526–534.
33. El-Tanani, M.K., Jin, D., Campbell, F.C., Johnston PG. Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression. Oncogene 29 (2010), 752–762.
34. Cheng, H.C., Liu, Y.P., Shan, Y.S., Huang, C.Y., Lin, F.C., Lin, L.C., et al. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer. Carcinogenesis 34 (2013), 2452–2459.
35. Bhattacharya, S.D., Garrison, J., Guo, H., Mi, Z., Markovic, J., Kim, V.M., et al. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 148 (2010), 291–297.
36. Shevde, L.A., Metge, B.J., Mitra, A., Xi, Y., Ju, J., King, J.A., et al. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J. Cell. Mol. Med. 14 (2010), 1693–1706.
37. Fok, T.C., Lapointe, H., Tuck, A.B., Chambers, A.F., Jackson-Boeters, L., Daley, T.D., et al. Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin alphavbeta3 in mucoepidermoid carcinoma and acinic cell adenocarcinoma of salivary gland origin. Oral. Surg. Oral Med. Oral Pathol. Oral Radiol. 118 (2014), 320–329.
38. Iwadate, H., Kobayashi, H., Kanno, T., Asano, T., Saito, R., Sato, S., et al. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int. J. Rheum. Dis. 17 (2014), 50–56.
39. Ihara, H., Denhardt, D.T., Furuya, K., Yamashita, T., Muguruma, Y., Tsuji, K., et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J. Biol. Chem. 276 (2001), 13065–13071.
40. Wesson, J.A., Johnson, R.J., Mazzali, M., Beshensky, A.M., Stietz, S., Giachelli, C., et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 14 (2003), 139–147.
41. Patarca, R., Freeman, G.J., Singh, R.P., Wei, F.Y., Durfee, T., Blattner, F., et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene: definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J. Exp. Med. 170 (1989), 145–161.
42. Rittling, S.R., Osteopontin in macrophage function. Expert Rev. Mol. Med., 13, 2011, e15.
43. Denhardt, D.T., Noda, M., O'Regan, A.W., Pavlin, D., Berman, J.S., Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107 (2001), 1055–1061.
44. Liaw, L., Birk, D.E., Ballas, C.B., Whitsitt, J.S., Davidson, J.M., Hogan, B.L., Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101 (1998), 1468–1478.
45. Kong, L.B., Ren, W.G., Mi, H.M., Zhao, S.X., Zhang, Y.G., Nan, Y.M., [Establishment of a complex alcoholic liver fibrosis mouse model and investigation of OPN and TGF-beta1 hepatic expression]. Zhonghua Gan Zang Bing Za Zhi 21 (2013), 207–212.
46. O'Regan, A., The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 14 (2003), 479–488.
47. Shi, S.M., Su, Z.B., Zhao, J.J., Yu, D.J., Tu, J.W., Zhu, J.Q., et al. Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: a meta analysis. J. Cancer Res. Ther. 12 (2016), 277–282.
48. Liu, Y., Gu, X., Lin, Q., Tian, T., Shao, L., Yuan, C., et al. Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis. Int. J. Clin. Exp. Med. 8 (2015), 12765–12773.
49. Zhang, J., Takahashi, K., Takahashi, F., Shimizu, K., Ohshita, F., Kameda, Y., et al. Differential osteopontin expression in lung cancer. Cancer Lett. 171 (2001), 215–222.
50. Li, D., Qian, W., Li, R.R., Zhang, J., Li, K.E., Wu, Y., Correlation between lung neoplasm and serum level of osteopontin: a meta-analysis. Biomed. Rep. 4 (2016), 567–572.
51. Furger, K.A., Menon, R.K., Tuck, A.B., Bramwell, V.H., Chambers, A.F., The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1 (2001), 621–632.
52. Cho, W.Y., Hong, S.H., Singh, B., Islam, M.A., Lee, S., Lee, A.Y., et al. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. Eur. J. Pharm. Biopharm. 94 (2015), 450–462.
53. Wu, Y., Denhardt, D.T., Rittling, S.R., Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer 83 (2000), 156–163.
54. Li, H., Liu, Y., Zhang, Q., Jing, Y., Chen, S., Song, Z., et al. Ras dependent paracrine secretion of osteopontin by Nf1+/− osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr. Res. 65 (2009), 613–618.
55. Martinez, C., Churchman, M., Freeman, T., Ilyas, M., Osteopontin provides early proliferative drive and may be dependent upon aberrant c-myc signalling in murine intestinal tumours. Exp. Mol. Pathol. 88 (2010), 272–277.
56. Lin, Q., Guo, L., Lin, G., Chen, Z., Chen, T., Lin, J., et al. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol. 39 (2015), 539–544.
57. Nemoto, H., Rittling, S.R., Yoshitake, H., Furuya, K., Amagasa, T., Tsuji, K., et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner. Res. 16 (2001), 652–659.
58. Urquidi, V., Sloan, D., Kawai, K., Agarwal, D., Woodman, A.C., Tarin, D., et al. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin. Cancer Res. 8 (2002), 61–74.
59. Behrend, E.I., Craig, A.M., Wilson, S.M., Denhardt, D.T., Chambers, A.F., Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54 (1994), 832–837.
60. Chen, H., Ke, Y., Oates, A.J., Barraclough, R., Rudland, P.S., Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14 (1997), 1581–1588.
61. Tuck, A.B., Hota, C., Wilson, S.M., Chambers, A.F., Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene 22 (2003), 1198–1205.
62. Tuck, A.B., Elliott, B.E., Hota, C., Tremblay, E., Chambers, A.F., Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem. 78 (2000), 465–475.
63. Kang, C.G., Han, H.J., Lee, H.J., Kim, S.H., Lee, E.O., Rho-associated kinase signaling is required for osteopontin-induced cell invasion through inactivating cofilin in human non-small cell lung cancer cell lines. Bioorg. Med. Chem. Lett. 25 (2015), 1956–1960.
64. Weber, G.F., The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2001), 61–85.
65. Blasberg, J.D., Goparaju, C.M., Pass, H.I., Donington, J.S., Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J. Thorac. Cardiovasc. Surg. 139 (2010), 1587–1593.
66. Yu, T.T., Han, Z.G., Shan, L., Tao, J., Zhang, T., Yuan, S.F., et al. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac. J. Cancer Preven. 15 (2014), 29–32.
67. Sangaletti, S., Tripodo, C., Sandri, S., Torselli, I., Vitali, C., Ratti, C., et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74 (2014), 4706–4719.
68. Ravindranath, A., Yuen, H.F., Chan, K.K., Grills, C., Fennell, D.A., Lappin, T.R., et al. Wnt-beta-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br. J. Cancer 105 (2011), 542–551.
69. El-Tanani, M., Barraclough, R., Wilkinson, M.C., Rudland, P.S., Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res. 61 (2001), 5619–5629.
70. Kumar, V., Behera, R., Lohite, K., Karnik, S., Kundu, G.C., p38 Kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res. 70 (2010), 10381–10391.
71. Yue, W., Sun, Q., Dacic, S., Landreneau, R.J., Siegfried, J.M., Yu, J., et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 29 (2008), 84–92.
72. Wang, Y., Yang, J., Liu, H., Bi, J.R., Liu, Y., Chen, Y.Y., et al. The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. OncoTargets Ther. 8 (2015), 3513–3521.
73. Han, S.S., Lee, S.J., Kim, W.J., Ryu, D.R., Won, J.Y., Park, S., et al. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc. Respir. Dis. 75 (2013), 104–110.
74. Zhou, Z., Chen, Z.W., Yang, X.H., Shen, L., Ai, X.H., Lu, S., et al. Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer. J. Exp. Clin. Cancer Res., 31, 2012, 34.
75. Liu, Y., Lei, H., Zhang, J., Wang, J., Li, K., Dong, W., Associations between the genetic polymorphisms of osteopontin promoter and susceptibility to cancer in chinese population: a meta-analysis. PLoS One, 10, 2015, e0135318.
76. Ramchandani, D., Weber, G.F., An osteopontin promoter polymorphism is associated with aggressiveness in breast cancer. Oncol. Rep. 30 (2013), 1860–1868.
77. Mu, G., Wang, H., Cai, Z., Ji, H., OPN–443C > T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort Cellular Physiology and Biochemistry. Cell. Physiol. Biochem. 32 (2013), 171–179.
78. Lee, T.Y., Lin, J.T., Wu, C.C., Yu, C.C., Wu, M.S., Lee, T.C., et al. Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J. Clin. Gastroenterol. 47 (2013), e55–9.
79. Chen, J., Wu, Q., Lu, Y., Xu, T., Huang, Y., Ribas, J., et al. SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J. Hum. Genet. 55 (2010), 456–461.
80. Hao, Y., Liu, J., Wang, P., Wang, F., Yu, Z., Li, M., et al. OPN polymorphism is related to the chemotherapy response and prognosis in advanced NSCLC. Int. J. Genomics, 2014, 2014, 846142.
81. Goparaju, C.M., Pass, H.I., Blasberg, J.D., Hirsch, N., Donington, J.S., Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J. Thorac. Oncol. 5 (2010), 1516–1523.
82. Tilli, T.M., Mello, K.D., Ferreira, L.B., Matos, A.R., Accioly, M.T., Faria, P.A., et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 72 (2012), 1688–1699.
83. Tilli, T.M., Thuler, L.C., Matos, A.R., Coutinho-Camillo, C.M., Soares, F.A., da Silva, E.A., et al. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia. Exp. Mol. Pathol. 92 (2012), 13–19.
84. Tilli, T.M., Franco, V.F., Robbs, B.K., Wanderley, J.L., da Silva, F.R., de Mello, K.D., et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol. Cancer Res. 9 (2011), 280–293.
85. Pang, H., Lu, H., Song, H., Meng, Q., Zhao, Y., Liu, N., et al. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer. Cancer Epidemiol. 37 (2013), 985–992.
86. Mirza, M., Shaughnessy, E., Hurley, J.K., Vanpatten, K.A., Pestano, G.A., He, B., et al. Osteopontin-c is a selective marker of breast cancer. Int. J. Cancer 122 (2008), 889–897.
87. Tang, X., Li, J., Yu, B., Su, L., Yu, Y., Yan, M., et al. Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int. J. Biol. Sci. 9 (2013), 55–66.
88. Agiostratidou, G., Hulit, J., Phillips, G.R., Hazan, R.B., Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J. Mammary Gland Biol. Neoplasia 12 (2007), 127–133.